Dr. Connie Wan is the founder and CEO of Seattle Gummy Company (SGC). Before founding SGC, Dr. Wan served as the Chief Technology and intellectual property Officer for Benemilk Oy, a joint venture by the Raisio Group and Intellectual Ventures (IV), the biggest patent-focused private equity fund in the world. During her tenure with Benemilk, Dr. Wan led the company’s product development, marketing, and sales, and was directly responsible for commercializing multiple products into the CN, JP, US, and EU markets. Before joining Benemilk, Dr. Wan led IV’s invention capital investments and assisted with asset creation, evaluation and acquisition, IP portfolio strategy and management, technology startup, partnership, joint venture formation, and technology licensing and commercialization.
Diversely experienced in scientific, business, and legal fields, her impressive background includes: researching novel therapeutics in both academic and industrial labs, developing cancer therapeutics, advising clients from blue-chip pharmaceutical companies such as Amgen, AstraZeneca, Daiichi-Sankyo, Immunex, and Teva to biotech startups such as Omeros as an IP attorney in private practice, and has previously co-founded several companies as a serial entrepreneur.
Connie earned multiple advanced degrees in various fields: a Bachelor of Science and Master of Medicine degrees from Peking University, a Master and Ph.D. from Clark University in organic chemistry, and a J.D. from the University of Washington, School of Law. She holds a patent bar license with USPTO as well as a law license in Washington state and is the incoming President for the Washington State Patent Law Association,
Recognized as a top IP strategist in the pharmaceutical and chemistry fields, Dr. Wan has a passion for bringing novel solutions to the pharmaceutical and nutritional space. She is published in numerous scientific journals, is a prolific inventor, and is a frequent speaker on science, business, law, and cross-cultural business dealings.
Connie founded Seattle Gummy Company in 2016 with the sole mission to improve how we administer medications. In that time, SGC has become the world leader in gummy medication technology with over 70 patent filings, 30+ trademarks, 10+ drugs in the FDA pipeline, and is the first company to receive IND gummy drug approval from the FDA.
You don’t have to wait for FDA approval to try these gummies. Check out SGC’s line of Functional Gummies RIGHT NOW!